超长因子VIII:迈向无血友病精神的重要一步
Cedric Hermans1, Glenn F Pierce2
1Division of Haematology, Haemostasis and Thrombosis Unit, Saint-Luc University Hospital, Université catholique de Louvain (UCLouvain), Brussels, Belgium; World Federation of Hemophilia, Montreal, Quebec, Canada.
Journal of thrombosis and haemostasis : JTH
|April 28, 2024
概括
一种新的超长因子VIII (FVIII) 疗法为A型血友病患者提供了前所未有的FVIII水平的多天校正. 这一突破提供了无与伦比的血静,改善了生活质量,尽管每周输液.
科学领域:
- 血液学 血液学 血液学
- 药理学 药理学是指药理学的学科.
- 生物技术是生物技术.
背景情况:
- 血友病A是一种遗传性出血障碍,由第八因子 (FVIII) 缺乏引起.
- 目前的治疗方法,包括延长半衰期的FVIII产品,需要频繁输注.
- 需要使用更长时间,更有效的FVIII疗法.
研究的目的:
- 介绍和描述efanesoctocog alfa,一种新的超长FVIII疗法.
- 突出技术进步,使FVIII活动延长.
- 将efanesoctocog alfa定位为A型血友病的新标准护理.
主要方法:
- 通过将FVIII与Fc片段融合并结合水友多来开发efanesoctocog alfa.
- 使用D'-D3片段将FVIII与·维勒布兰德因子断开.
- 药理动力学研究,以评估efanesoctocog alfa的延长半衰期和活性.
主要成果:
- 在几天内,Efanesoctocog alfa在正常范围内达到FVIII水平.
- 这种分子的药物动力学延长优于现有的延长半衰期FVIII产品.
- 这种治疗提供了无与伦比的血静纠正幅度和持续时间.
结论:
- 埃法尼索克托科格阿尔法 (Efanesoctocog alfa) 代表了A型血友病治疗的重大进展.
- 超长FVIII疗法为改善血液静止和患者的生活质量提供了一个新时代.
- 每周输注efanesoctocog alfa提供了持续的治疗效益,目前的选择无法与之匹敌.
相关概念视频
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
687
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
687
01:20Extrinsic and Intrinsic Pathways of Hemostasis
7.3K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.3K
01:24Disorders of Hemostasis
872
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
872